180 related articles for article (PubMed ID: 29747600)
1. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM
BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600
[TBL] [Abstract][Full Text] [Related]
2. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
3. Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.
Labussière M; Cheneau C; Prahst C; Gállego Pérez-Larraya J; Farina P; Lombardi G; Mokhtari K; Rahimian A; Delattre JY; Eichmann A; Sanson M
Cancer Invest; 2016; 34(1):39-44. PubMed ID: 26735326
[TBL] [Abstract][Full Text] [Related]
4. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.
Tabouret E; Boudouresque F; Barrie M; Matta M; Boucard C; Loundou A; Carpentier A; Sanson M; Metellus P; Figarella-Branger D; Ouafik L; Chinot O
Neuro Oncol; 2014 Mar; 16(3):392-9. PubMed ID: 24327581
[TBL] [Abstract][Full Text] [Related]
5. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
Kickingereder P; Götz M; Muschelli J; Wick A; Neuberger U; Shinohara RT; Sill M; Nowosielski M; Schlemmer HP; Radbruch A; Wick W; Bendszus M; Maier-Hein KH; Bonekamp D
Clin Cancer Res; 2016 Dec; 22(23):5765-5771. PubMed ID: 27803067
[TBL] [Abstract][Full Text] [Related]
6. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
Bertaut A; Truntzer C; Madkouri R; Kaderbhai CG; Derangère V; Vincent J; Chauffert B; Aubriot-Lorton MH; Farah W; Mourier KL; Boidot R; Ghiringhelli F
Oncotarget; 2016 Oct; 7(43):70948-70958. PubMed ID: 27487142
[TBL] [Abstract][Full Text] [Related]
7. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
8. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
PLoS One; 2016; 11(12):e0168113. PubMed ID: 28033329
[TBL] [Abstract][Full Text] [Related]
9. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
Di Stefano AL; Labussiere M; Lombardi G; Eoli M; Bianchessi D; Pasqualetti F; Farina P; Cuzzubbo S; Gallego-Perez-Larraya J; Boisselier B; Ducray F; Cheneau C; Moglia A; Finocchiaro G; Marie Y; Rahimian A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
J Neurooncol; 2015 Feb; 121(3):499-504. PubMed ID: 25488073
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
11. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
12. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
15. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
16. VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma.
D'Alessandris QG; Martini M; Cenci T; Capo G; Ricci-Vitiani L; Larocca LM; Pallini R
Neurology; 2015 May; 84(18):1906-8. PubMed ID: 25862796
[No Abstract] [Full Text] [Related]
17. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Galanis E; Anderson SK; Lafky JM; Uhm JH; Giannini C; Kumar SK; Kimlinger TK; Northfelt DW; Flynn PJ; Jaeckle KA; Kaufmann TJ; Buckner JC
Clin Cancer Res; 2013 Sep; 19(17):4816-23. PubMed ID: 23833308
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
19. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
20. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Sorensen AG; Batchelor TT; Zhang WT; Chen PJ; Yeo P; Wang M; Jennings D; Wen PY; Lahdenranta J; Ancukiewicz M; di Tomaso E; Duda DG; Jain RK
Cancer Res; 2009 Jul; 69(13):5296-300. PubMed ID: 19549889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]